- Home
- EXEL vs BXP Comparison
EXEL vs BXP Comparison
Compare EXEL & BXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- BXP
- Stock Information
- Founded
- EXEL 1994
- BXP 1970
- Country
- EXEL United States
- BXP United States
- Employees
- EXEL N/A
- BXP N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- BXP Real Estate Investment Trusts
- Sector
- EXEL Health Care
- BXP Real Estate
- Exchange
- EXEL Nasdaq
- BXP Nasdaq
- Market Cap
- EXEL 11.3B
- BXP 10.4B
- IPO Year
- EXEL 2000
- BXP 1997
- Fundamental
- Price
- EXEL $44.08
- BXP $66.84
- Analyst Decision
- EXEL Buy
- BXP Buy
- Analyst Count
- EXEL 18
- BXP 14
- Target Price
- EXEL $43.00
- BXP $79.57
- AVG Volume (30 Days)
- EXEL 3.3M
- BXP 2.0M
- Earning Date
- EXEL 08-05-2025
- BXP 07-29-2025
- Dividend Yield
- EXEL N/A
- BXP 5.71%
- EPS Growth
- EXEL 237.58
- BXP N/A
- EPS
- EXEL 2.20
- BXP N/A
- Revenue
- EXEL $2,298,922,000.00
- BXP $3,397,133,000.00
- Revenue This Year
- EXEL $9.37
- BXP $2.42
- Revenue Next Year
- EXEL $11.05
- BXP $2.80
- P/E Ratio
- EXEL $19.98
- BXP N/A
- Revenue Growth
- EXEL 24.49
- BXP 3.47
- 52 Week Low
- EXEL $21.82
- BXP $54.22
- 52 Week High
- EXEL $49.62
- BXP $90.11
- Technical
- Relative Strength Index (RSI)
- EXEL 57.96
- BXP 43.18
- Support Level
- EXEL $42.66
- BXP $66.57
- Resistance Level
- EXEL $49.62
- BXP $72.69
- Average True Range (ATR)
- EXEL 1.58
- BXP 1.88
- MACD
- EXEL 0.10
- BXP -0.74
- Stochastic Oscillator
- EXEL 43.24
- BXP 15.09
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.